SOLO-1 is the first, double-blind, randomized, prospective Phase III trial to evaluate front-line olaparib maintenance therapy after platinum-based chemotherapy in newly diagnosed advanced ovarian cancer with BRCA mutation.
Browsing: Disease Area > Gynecologic
Two-year maintenance therapy with olaparib improves PFS in newly diagnosed patients with advanced ovarian cancer with a BRCA1 or 2 mutation.
A combination of the targeted drug vistusertib with paclitaxel chemotherapy has shown promise in an early clinical trial, in patients with ovarian or lung cancer for whom all other treatments had failed.
Researchers have revealed that the use of Lynparza® to treat BRCA-mutated ovarian cancer results in a significant improvement in progression-free survival.
A recent study has demonstrated a significant decrease in cases of HPV infections in England since the introduction of a bivalent vaccine in 2008.
A team of researchers have identified the cause of resistance to breakthrough breast and ovarian cancer drugs.
Investigators have discovered why Huntington’s disease is so toxic to cancer cells and are harnessing it as a novel approach to treat cancer.
Discover details of the first randomized, multicenter Phase III study to compare the safety and efficacy of mirvetuximab soravtansine vs investigator’s choice of chemotherapy in women with folate receptor-α-positive, platinum-resistant epithelial ovarian, primary peritoneal or fallopian tube cancer.
Discover the case of a heavily pretreated patient with recurrent advanced squamous cell carcinoma of the cervix who had exhausted all available treatments and demonstrated a striking response to pembrolizumab.